DreamCIS Inc (223250) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DreamCIS Inc (223250) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.17 Billion ≈ $1.47 Million USD) by net assets (₩92.81 Billion ≈ $62.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DreamCIS Inc market capitalisation for the company's overall valuation and market capitalisation.
DreamCIS Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how DreamCIS Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
DreamCIS Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DreamCIS Inc ranked by their cash flow conversion efficiency. Explore DreamCIS Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Erbosan Erciyas Boru Sanayi Ve Ticaret AS
IS:ERBOS
|
0.013x |
|
Dreadnought Resources Ltd
AU:DRE
|
-0.014x |
|
Cimbeton Hazirbeton ve Prefabrik Yapi Elemanlari Sanayi ve Ticaret AS
IS:CMBTN
|
0.316x |
|
Online Brands Nordic AB
ST:OBAB
|
-0.062x |
|
DSK Co. Ltd
KQ:109740
|
-0.018x |
|
Neo-Concept International Group Holdings Limited Ordinary Shares
NASDAQ:NCI
|
0.008x |
|
SkyAI, Inc.
NASDAQ:SKYA
|
-0.019x |
|
Yoong Onn Corporation Bhd
KLSE:5159
|
0.058x |
Annual Cash Flow Conversion Efficiency for DreamCIS Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of DreamCIS Inc from 2017 to 2024. View today's stock price for DreamCIS Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩67.96 Billion ≈ $46.06 Million |
₩-85.19 Million ≈ $-57.73K |
-0.001x | -100.97% |
| 2023-12-31 | ₩56.93 Billion ≈ $38.58 Million |
₩7.33 Billion ≈ $4.97 Million |
0.129x | -30.57% |
| 2022-12-31 | ₩48.96 Billion ≈ $33.18 Million |
₩9.08 Billion ≈ $6.16 Million |
0.186x | +19.79% |
| 2021-12-31 | ₩37.98 Billion ≈ $25.74 Million |
₩5.88 Billion ≈ $3.99 Million |
0.155x | +65.10% |
| 2020-12-31 | ₩36.46 Billion ≈ $24.71 Million |
₩3.42 Billion ≈ $2.32 Million |
0.094x | -76.46% |
| 2019-12-31 | ₩10.75 Billion ≈ $7.28 Million |
₩4.28 Billion ≈ $2.90 Million |
0.398x | -46.58% |
| 2018-12-31 | ₩6.51 Billion ≈ $4.41 Million |
₩4.85 Billion ≈ $3.29 Million |
0.746x | +27.42% |
| 2017-12-31 | ₩2.82 Billion ≈ $1.91 Million |
₩1.65 Billion ≈ $1.12 Million |
0.585x | -- |
About DreamCIS Inc
DreamCIS, Inc. operates as a clinical research organization in South Korea. It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headqua… Read more